Last update Sept. 19, 2016

キンファミド

Compatible

Safe substance and/or breastfeeding is the best option.

Antiamoebic agent with intraluminal action.

At latest update no published data were found regarding breastfeeding.

Its low intestinal absorption makes it highly unlikely the passage of significant amounts into breast milk as well as it would not be absorbed by the infant intestine.

Alternatives

We do not have alternatives for キンファミド since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

キンファミド is Quinfamide in Japanese.

Is written in other languages:

Group

キンファミド belongs to this group or family:

Tradenames

Main tradenames from several countries containing キンファミド in its composition:

List of 11 tradenames
  • Amefin™
  • Amenox™
  • Amoebriz™. Contains other elements than キンファミド in its composition
  • Bensolmin Complex ™. Contains other elements than キンファミド in its composition
  • Bisidim™
  • Farmiver™. Contains other elements than キンファミド in its composition
  • Loxcell NF ™. Contains other elements than キンファミド in its composition
  • Luminovag™
  • Oxal™. Contains other elements than キンファミド in its composition
  • Serphamida™
  • Vermox-Plus™. Contains other elements than キンファミド in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Baja - Poor %
Molecular weight 354 daltons

References

  1. ROMERO-CABELLO, RAÚL et al. Evaluation of the efficacy and security of quinfamide administered in a single dose of 300 mg in adult patients with intestinal amebiasis. Parasitol. latinoam. 2005, vol.60, n.1-2, pp.57-60. 2005 Full text (link to original source) Full text (in our servers)

Total visits

1,893

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM